Company profile: Simcha Therapeutics
1.1 - Company Overview
Company description
- Provider of engineered cytokine immunotherapies for cancer, including ST-067, an engineered IL-18 variant designed to overcome the IL-18BP decoy receptor, in Phase 1 trials for solid tumors; ST-067 plus Keytruda® in Phase 1; preclinical ST-067 combination therapies; and undisclosed cytokine therapeutic programs.
Products and services
- ST-067 | Keytruda® Combination Therapy: A clinical-stage combination of ST-067 and Keytruda (pembrolizumab) evaluated in Phase 1 for patients with solid tumors, pairing cytokine immunotherapy with pembrolizumab
- ST-067: An engineered variant of human IL-18 that circumvents the IL-18BP decoy receptor, in Phase 1 for solid tumors to activate cytokine immunotherapy
- Undisclosed ST-067 Combination Therapies: Preclinical-stage programs exploring various combination therapies involving ST-067 for cancer, expanding cytokine immunotherapy approaches and defining potential regimens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Simcha Therapeutics
GT Biopharma
HQ: United States
Website
- Description: Provider of TriKE immunotherapy technology that bridges natural killer cells to cancer cells to boost anti-tumor responses. Pipeline includes GTB-3550 for CD33+ leukemias (AML, high-risk MDS), GTB-3650 using camelid nanobodies for CD33+ leukemias, and GTB-5550, GTB-4550, GTB-6550 for B7H3, PD-L1, and HER2 positive solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GT Biopharma company profile →
Palleon Pharmaceuticals
HQ: United States
Website
- Description: Provider of glycoimmune checkpoint inhibitors to treat cancer, including E-602, a bi-sialidase fusion protein in Phase 1/2 trials that degrades immunosuppressive sialoglycans to restore antitumor immunity; the EAGLE platform of engineered human sialidases to strip sialic acid from cancer and immune cells; HYDRA immunohistochemistry technology to quantify sialoglycan density; and autoimmune disease R&D programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Palleon Pharmaceuticals company profile →
Grid Therapeutics
HQ: United States
Website
- Description: Provider of AI-driven platforms and therapeutics for cancer, including GT103, a human-derived antibody targeting a tumor-specific epitope for lung and other cancers. Offerings include high-throughput antibody discovery without prior protein knowledge, an AI-driven data warehouse, computational biology tools, a tumor vaccine design program, and a Phase 1b NSCLC study of GT103.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Grid Therapeutics company profile →
4-Antibody
HQ: Switzerland
Website
- Description: Provider of a human antibody drug-discovery platform focused on immuno-oncology, leveraging Retrocyte Display to generate therapeutic antibody candidates from human libraries expressed in mammalian B-lineage lymphocytes, and developer of a pipeline including Botensilimab (CTLA-4), Balstilimab (PD-1), Zalifrelimab (CTLA-4), AGEN2373 (anti-CD137), AGEN1571 (ILT-2) and ILT4 antagonists, with ongoing clinical trials across multiple cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4-Antibody company profile →
CEL-SCI
HQ: United States
Website
- Description: Provider of immunotherapy products and technology targeting cancer and infectious diseases, including Multikine, an investigational therapy for advanced primary head and neck cancer intended for use before any other therapy; LEAPS, a platform with candidates for rheumatoid arthritis and other autoimmune and infectious diseases; and a global Phase III trial of Multikine aiming to support potential FDA approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CEL-SCI company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Simcha Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Simcha Therapeutics
2.2 - Growth funds investing in similar companies to Simcha Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Simcha Therapeutics
4.2 - Public trading comparable groups for Simcha Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →